USC Cardiologia, Dipartimento Cardiovascolare, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy.
Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):49-61. doi: 10.1586/erp.10.1.
Drug-eluting stents substantially reduce restenosis compared with bare-metal stents and represent a significant advance in percutaneous coronary interventions. Accordingly, drug-eluting stents have been rapidly adopted into practice and are currently used in the vast majority of complex percutaneous coronary procedures. However, in the last 2 years, concerns have been raised regarding their long-term safety, especially regarding the risk of late and very-late stent thrombosis. Delayed endothelial coverage after drug-eluting stent implantation is thought to prolong the window of vulnerability to stent thrombosis, which requires a prolonged dual antiplatelet therapy. Recent registry studies and meta-analyses seem to have provided reassuring results regarding the long-term rates of death and myocardial infarction associated with the use of drug-eluting stents compared with bare-metal stents. However, data are not consistent and concerns remain.
药物洗脱支架与裸金属支架相比,可显著降低再狭窄率,是经皮冠状动脉介入治疗的重大进展。因此,药物洗脱支架已迅速被广泛应用于临床实践中,目前已被广泛应用于绝大多数复杂的经皮冠状动脉介入手术中。然而,在过去的 2 年中,人们对其长期安全性提出了担忧,尤其是关于晚期和极晚期支架内血栓形成的风险。药物洗脱支架植入后内皮覆盖延迟被认为延长了支架内血栓形成的易损窗口,这需要更长时间的双联抗血小板治疗。最近的登记研究和荟萃分析似乎提供了令人放心的结果,表明与裸金属支架相比,药物洗脱支架的使用与死亡率和心肌梗死的长期发生率相关。然而,数据并不一致,担忧仍然存在。